Form 4: Immunome CEO Receives Stock Grant
Insider Transaction (Form 4)
Clay B Siegall, President and CEO and a Director of Immunome Inc., reported multiple transactions in common stock on July 23, 2026.
Summary
- Grant/award: acquired 180,000 Common Stock on July 23, 2026; holds 870,704 after (Direct).
- Grant/award: acquired 360,000 Employee Stock Option (right to buy) on July 23, 2026; holds 360,000 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Clay B Siegall — Director, Officer (President and CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-23 | Grant/award | Common Stock | 180,000 | — | — | 870,704 |
| 2026-07-23 | Grant/award | Employee Stock Option (right to buy) | 360,000 | — | — | 360,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-23 | Grant/award (180,000 shares) |
| 2026-07-23 | Grant/award (360,000 shares) |
Keywords
insider transaction, Form 4, IMNM, Immunome Inc., neutral, Clay B Siegall
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.